Reports
Sale
Global Hepatic Disease Treatment Market Size, Forecast: By Treatment Type: Antiviral Drugs, Immunoglobulins, Immunosuppressants, Vaccines, Corticosteroids, Chemotherapy, Targeted Therapy, Others; By Disease Type: Hepatitis, Autoimmune Diseases, NAFLD, Others; By End Use; Regional Analysis; Competitive Landscape; 2024-2032
Global Hepatic Disease Treatment Market Outlook
The global market for hepatic disease treatment reached a value of about USD 24.78 billion in 2023. The market is further expected to grow at a CAGR of about 6.2% in the forecast period of 2024-2032 to reach a value of around USD 42.50 billion by 2032, owing to the rising prevalence of liver diseases.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America and Asia Pacific to be Significant Regional Markets for Hepatic Disease Treatment
Due to a large number of research and academic institutes conducting clinical trial studies in the region, North America is likely to be the dominant region in the hepatic disease treatment market over the forecast period. Changes in lifestyle, such as increasing alcohol consumption and poor diet, have also contributed to a rise in the prevalence of the liver disease. Further, increased patient awareness and the launch of innovative products that address unmet medical needs are expected to drive the regional market growth throughout the forecast period. The number of deaths caused by liver illnesses has increased, as has the frequency of liver cancer. According to the Centres for Disease Control and Prevention, roughly 800,000 to 1.4 million Americans have chronic hepatitis B virus (HBV) infection, and hepatitis B is the underlying cause of 2,000 to 4,000 fatalities in the United States each year.
Asia Pacific is projected to have the fastest growth owing to rapidly increasing healthcare infrastructure, increased spending, government initiatives and increasing awareness amongst the population, and the growing medical tourism industry in developing nations, such as China and India. Another factor driving the market growth is the rapidly increasing need for improved and innovative liver disease therapies, notably in China, India, and South Korea. Also, one of the significant factors behind this growth can be the increasing prevalence of non-alcoholic fatty liver disease (NAFLD) and hepatitis, lack of expertise, and the poor healthcare infrastructure in the region. Further, the region's ageing population, combined with major growth in overweight and obesity rates in China and Australia, is increasing the risk of liver disease, which is projected to drive demand for the hepatic disease treatment market in Asia Pacific.
Market Segmentations
Hepatic disease is caused in the liver; it refers to a variety of disorders that impair or prevent the liver from functioning properly. Yellowing of the skin or eyes (jaundice), abdominal pain, or abnormal liver function test results may indicate liver illness. Common liver ailments include cancer, hepatitis, autoimmune diseases, and genetic problems. Treatment for liver disease improves cholesterol and hormone excretion by increasing bile synthesis and enzyme activation.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on treatment type, the market is divided into:
- Antiviral Drugs
- Immunoglobulins
- Immunosuppressants
- Vaccines
- Corticosteroids
- Chemotherapy
- Targeted Therapy
- Others
The various types of diseases in the hepatic disease treatment market are:
- Hepatitis
- Autoimmune Diseases
- Non-alcoholic Fatty Liver Disease (NAFLD)
- Cancer
- Genetic Disorders
- Others
The end-uses of the market are:
- Hospitals
- Ambulatory Surgery Centres
- Others
The regional markets for hepatic disease treatment can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rise in the Prevalence of Liver Diseases Propelling the Market Growth
The rise in the prevalence of liver diseases, such as non-alcoholic fatty liver disease (NAFLD), liver cirrhosis, hepatitis, alcoholic hepatitis, and liver cancer worldwide is largely due to an unhealthy lifestyle and excessive alcohol consumption. This is propelling the global hepatic disease treatment market. One of the primary factors augmenting the global market's growth is the world's growing geriatric population, which is susceptible to a variety of chronic diseases, including liver disease. Accordingly, the quick acceptance of antiviral medications, which are safe and efficient in suppressing the hepatitis B virus and lowering the risk of developing cirrhosis and hepatocellular carcinoma, is favourably influencing the market growth. Moreover, increasing research and development activities, significant growth in the healthcare industry and implementation of various government initiatives in order to promote public health are creating a positive outlook for the market. For instance, in February 2021, the Indian government announced the integration of NAFLD with the National Program for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS). This program is mainly focused on multiple factors, including early diagnosis and management of NAFLD, along with building healthcare infrastructure for the prevention, diagnosis, and treatment of NAFLD.
Key Players in the Global Market for Hepatic Disease Treatment
The report gives a detailed analysis of the following key players in the global hepatic disease treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- AbbVie Inc.
- Abbott Laboratories
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- Gilead Sciences, Inc.
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Disease Type |
|
| Breakup by End Use |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Hepatic Disease Treatment Market Analysis
8.1 Key Industry Highlights
8.2 Global Hepatic Disease Treatment Historical Market (2018-2023)
8.3 Global Hepatic Disease Treatment Market Forecast (2024-2032)
8.4 Global Hepatic Disease Treatment Market by Treatment Type
8.4.1 Antiviral Drugs
8.4.1.1 Historical Trend (2018-2023)
8.4.1.2 Forecast Trend (2024-2032)
8.4.2 Immunoglobulins
8.4.2.1 Historical Trend (2018-2023)
8.4.2.2 Forecast Trend (2024-2032)
8.4.3 Immunosuppressants
8.4.3.1 Historical Trend (2018-2023)
8.4.3.2 Forecast Trend (2024-2032)
8.4.4 Vaccines
8.4.4.1 Historical Trend (2018-2023)
8.4.4.2 Forecast Trend (2024-2032)
8.4.5 Corticosteroids
8.4.5.1 Historical Trend (2018-2023)
8.4.5.2 Forecast Trend (2024-2032)
8.4.6 Chemotherapy
8.4.6.1 Historical Trend (2018-2023)
8.4.6.2 Forecast Trend (2024-2032)
8.4.7 Targeted Therapy
8.4.7.1 Historical Trend (2018-2023)
8.4.7.2 Forecast Trend (2024-2032)
8.4.8 Others
8.5 Global Hepatic Disease Treatment Market by Disease Type
8.5.1 Hepatitis
8.5.1.1 Historical Trend (2018-2023)
8.5.1.2 Forecast Trend (2024-2032)
8.5.2 Autoimmune Diseases
8.5.2.1 Historical Trend (2018-2023)
8.5.2.2 Forecast Trend (2024-2032)
8.5.3 Non-alcoholic Fatty Liver Disease (NAFLD)
8.5.3.1 Historical Trend (2018-2023)
8.5.3.2 Forecast Trend (2024-2032)
8.5.4 Cancer
8.5.4.1 Historical Trend (2018-2023)
8.5.4.2 Forecast Trend (2024-2032)
8.5.5 Genetic Disorders
8.5.5.1 Historical Trend (2018-2023)
8.5.5.2 Forecast Trend (2024-2032)
8.5.6 Others
8.6 Global Hepatic Disease Treatment Market by End Use
8.6.1 Hospitals
8.6.1.1 Historical Trend (2018-2023)
8.6.1.2 Forecast Trend (2024-2032)
8.6.2 Ambulatory Surgical Centres
8.6.2.1 Historical Trend (2018-2023)
8.6.2.2 Forecast Trend (2024-2032)
8.6.3 Others
8.7 Global Hepatic Disease Treatment Market by Region
8.7.1 North America
8.7.1.1 Historical Trend (2018-2023)
8.7.1.2 Forecast Trend (2024-2032)
8.7.2 Europe
8.7.2.1 Historical Trend (2018-2023)
8.7.2.2 Forecast Trend (2024-2032)
8.7.3 Asia Pacific
8.7.3.1 Historical Trend (2018-2023)
8.7.3.2 Forecast Trend (2024-2032)
8.7.4 Latin America
8.7.4.1 Historical Trend (2018-2023)
8.7.4.2 Forecast Trend (2024-2032)
8.7.5 Middle East and Africa
8.7.5.1 Historical Trend (2018-2023)
8.7.5.2 Forecast Trend (2024-2032)
9 North America Hepatic Disease Treatment Market Analysis
9.1 United States of America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.2 Canada
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
10 Europe Hepatic Disease Treatment Market Analysis
10.1 United Kingdom
10.1.1 Historical Trend (2018-2023)
10.1.2 Forecast Trend (2024-2032)
10.2 Germany
10.2.1 Historical Trend (2018-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 France
10.3.1 Historical Trend (2018-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 Italy
10.4.1 Historical Trend (2018-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Others
11 Asia Pacific Hepatic Disease Treatment Market Analysis
11.1 China
11.1.1 Historical Trend (2018-2023)
11.1.2 Forecast Trend (2024-2032)
11.2 Japan
11.2.1 Historical Trend (2018-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 India
11.3.1 Historical Trend (2018-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 ASEAN
11.4.1 Historical Trend (2018-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 Australia
11.5.2 Historical Trend (2018-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Others
12 Latin America Hepatic Disease Treatment Market Analysis
12.1 Brazil
12.1.1 Historical Trend (2018-2023)
12.1.2 Forecast Trend (2024-2032)
12.2 Argentina
12.2.1 Historical Trend (2018-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Mexico
12.3.1 Historical Trend (2018-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Others
13 Middle East and Africa Hepatic Disease Treatment Market Analysis
13.1 Saudi Arabia
13.1.1 Historical Trend (2018-2023)
13.1.2 Forecast Trend (2024-2032)
13.2 United Arab Emirates
13.2.1 Historical Trend (2018-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 Nigeria
13.3.1 Historical Trend (2018-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 South Africa
13.4.1 Historical Trend (2018-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
15 Value Chain Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Company Profiles
16.2.1 AbbVie Inc.
16.2.1.1 Company Overview
16.2.1.2 Product Portfolio
16.2.1.3 Demographic Reach and Achievements
16.2.1.4 Certifications
16.2.2 Abbott Laboratories
16.2.2.1 Company Overview
16.2.2.2 Product Portfolio
16.2.2.3 Demographic Reach and Achievements
16.2.2.4 Certifications
16.2.3 Merck & Co., Inc.
16.2.3.1 Company Overview
16.2.3.2 Product Portfolio
16.2.3.3 Demographic Reach and Achievements
16.2.3.4 Certifications
16.2.4 F. Hoffmann-La Roche Ltd
16.2.4.1 Company Overview
16.2.4.2 Product Portfolio
16.2.4.3 Demographic Reach and Achievements
16.2.4.4 Certifications
16.2.5 Eli Lilly and Company
16.2.5.1 Company Overview
16.2.5.2 Product Portfolio
16.2.5.3 Demographic Reach and Achievements
16.2.5.4 Certifications
16.2.6 Bristol-Myers Squibb Company
16.2.6.1 Company Overview
16.2.6.2 Product Portfolio
16.2.6.3 Demographic Reach and Achievements
16.2.6.4 Certifications
16.2.7 Gilead Sciences, Inc.
16.2.7.1 Company Overview
16.2.7.2 Product Portfolio
16.2.7.3 Demographic Reach and Achievements
16.2.7.4 Certifications
16.2.8 Others
17 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Hepatic Disease Treatment Market: Key Industry Highlights, 2018 and 2032
2. Global Hepatic Disease Treatment Historical Market: Breakup by Treatment Type (USD Billion), 2018-2023
3. Global Hepatic Disease Treatment Market Forecast: Breakup by Treatment Type (USD Billion), 2024-2032
4. Global Hepatic Disease Treatment Historical Market: Breakup by Disease Type (USD Billion), 2018-2023
5. Global Hepatic Disease Treatment Market Forecast: Breakup by Disease Type (USD Billion), 2024-2032
6. Global Hepatic Disease Treatment Historical Market: Breakup by End Use (USD Billion), 2018-2023
7. Global Hepatic Disease Treatment Market Forecast: Breakup by End Use (USD Billion), 2024-2032
8. Global Hepatic Disease Treatment Historical Market: Breakup by Region (USD Billion), 2018-2023
9. Global Hepatic Disease Treatment Market Forecast: Breakup by Region (USD Billion), 2024-2032
10. North America Hepatic Disease Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
11. North America Hepatic Disease Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
12. Europe Hepatic Disease Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
13. Europe Hepatic Disease Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
14. Asia Pacific Hepatic Disease Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
15. Asia Pacific Hepatic Disease Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
16. Latin America Hepatic Disease Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
17. Latin America Hepatic Disease Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
18. Middle East and Africa Hepatic Disease Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
19. Middle East and Africa Hepatic Disease Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
20. Global Hepatic Disease Treatment Market Structure.
Key Questions Answered in the Report
In 2023, the global hepatic disease treatment market attained a value of nearly USD 24.78 billion.
The market is projected to grow at a CAGR of 6.2% between 2024 and 2032.
The market is estimated to witness healthy growth in the forecast period of 2024-2032 to reach USD 42.50 billion by 2032.
The major drivers of the market include the increasing awareness amongst the population, increasing need for improved and innovative liver disease therapies, unhealthy lifestyle and excessive alcohol consumption, increasing alcohol consumption, increasing research and development activities, and government initiatives.
The rise in the prevalence of liver diseases and the growing geriatric population are the key industry trends propelling the growth of the market.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
Based on treatment type, the market is divided into antiviral drugs, immunoglobulins, immunosuppressants, vaccines, corticosteroids, chemotherapy, and targeted therapy, among others.
The various types of diseases in the market are hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, and genetic disorders, among others.
The end-uses of the market are hospitals and ambulatory surgery centres, among others.
The major players in the industry are AbbVie Inc., Abbott Laboratories, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Bristol-Myers Squibb Company, and Gilead Sciences, Inc., among others.
Analyst Review
The global hepatic disease treatment market attained a value of nearly USD 24.78 billion, driven by the rise in the prevalence of liver diseases. Aided by the increasing alcohol consumption and growing geriatric population, the market is expected to grow at a CAGR of 6.2% in the forecast period of 2024-2032. The market is estimated to reach USD 42.50 billion by 2032.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on treatment type, the market is divided into antiviral drugs, immunoglobulins, immunosuppressants, vaccines, corticosteroids, chemotherapy, and targeted therapy, among others. The various types of diseases in the market are hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, and genetic disorders, among others. The end-uses of the market are hospitals and ambulatory surgery centres, among others. The major regional markets for hepatic disease treatment are North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa. The key players in the above market are AbbVie Inc., Abbott Laboratories, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Bristol-Myers Squibb Company, and Gilead Sciences, Inc., among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER